Media OutReach
Bora Navigates A Transitional 1Q26 And Sets A Strong Foundation For Rest Of The Year
Transformational Acquisitions Expected to Contribute to Long Term Growth Starting 2Q26
HONG KONG SAR – Media OutReach Newswire – 13 May 2026 – Bora Pharmaceuticals (“Bora”; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for 1Q2026 and provides full year outlook.
1Q26 Business and Financial Highlights
- The Company reported 1Q26 revenues of NT$4,001 million, down 17.68% sequentially, with basic EPS of NT$0.21. Gross margin stabilized quarter-over-quarter. The quarter reflected temporary slowdown across both businesses: pricing and demand variability in the generics market through January and February left Upsher-Smith’s 1Q26 revenue 18.63% below the trailing four-quarter run rate, while the scheduled annual maintenance of 6 weeks of our Maryland fill-finish facility limited fixed-cost absorption during the quarter, weighed on earnings quality.
- March saw a rebound in both businesses as conditions improved for both the top and bottom lines with steady demand. During the quarter, the Company advanced Maple Grove site ramp-up significantly, with several multi-year CDMO agreements signed or progressing across pharma clients of various sizes. Additionally, the Company continues to win new CDMO business as 12-month rolling backlog arrived at US$315 million. With a healthy order book at North American sites entering the second quarter, we expect fixed-cost leverage to resume, driving profit improvement as utilization builds across the installed asset base. Meanwhile, Upsher-Smith has successfully defended market share and is deploying lifecycle management initiatives that reinforce our ability to set the cadence of sales in a dynamic competitive environment.
- Non-operating loss primarily reflected a wider equity loss from affiliate Tanvex Biopharma, together with higher tax expense driven by annual 1Q recognition of tax from undistributed earnings of the previous year.
- Disciplined OPEX control has driven expenses down 14.87% quarter-over-quarter and 14.41% year-over-year. This signals that resources have settled in as we begin to see advantages in scale; The Company expects ROA and ROIC to trend gradually upward, albeit with some quarter-to-quarter variability as operating leverage builds.
- Board of Directors approved the acquisition of the CDMO business of MacroGenics Inc. (NASDAQ: MGNX), for total consideration of US$122.5 million, leading to a total 12-month rolling backlog upon closing to approximately US$375 million.
- Sunway Biotech’s Board approved the 100% acquisition of Weider Global Nutrition (“WGN”), an iconic Phoenix-based American sports nutrition brand with a strategic Costco U.S. supplier relationship, commercial presence in 60+ countries, and established positions on Amazon and Walmart. The transaction completes Bora Group’s three-platform architecture, namely CDMO, pharma sales, and nutraceuticals operated under our “dual engine” strategy.
- Share capital increased 0.04% during the quarter from employee stock option exercise.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “The beginning of 2026 was eventful and challenging both in the world and at Bora. We have seen supply chain disruptions, inflation from wars, and continuous geopolitical tensions. Yet through it all, Bora Group’s disciplined approach to growth-oriented investment remained unwavering.
Our CDMO business CAPEX-to-revenue ratio reached an all-time high of over 10% in 2025, marking another year of upward progression and bringing the Company to a level comparable with established global CDMO peers. This marked a deliberate shift in where we direct investments from capacity-led expansion that defined our earlier growth chapters to a sharper focus on capability demands and modality, anchored in innovation and technology. Over the past 18 months, we have pursued an ambitious growth trajectory against a dynamic macroeconomic backdrop – recalibrating expectations, sharpening our strategy, and reaffirming long-term plans. The underlying demand environment supports our conviction: global pharma is growing at 5-8% per year, biologics CDMO outsourcing demand at 15%+ and small-molecule outsourcing demand at 8-10%. With our investment foundation now in place, we believe our CDMO business is positioned to compound organically at 13-23% annually.
In the first quarter, we executed a series of organizational adjustments, each aligned to a specific dimension of customer demand. We established the MSAT (Manufacturing, Science and Technology) function within the CDMO business, the R&D backbone of the platform, to deepen scientific and technical capability across our entire client base, an increasingly critical asset as small and mid-sized biotech and pharma clients rethink their supply chain. In parallel, we repurposed the Strategic Enterprise Account Management team into a networked model to serve clients for whom customer proximity is paramount. Together, these capability investments target specific customer pain points and position Bora to navigate the evolving political and economic landscape and capture a new chapter of commercial momentum.
To sum up, CDMO business in 1Q26 delivered US$27.2 million in total external wins on top of orders on hand, 60% or 7 molecules from pre-commercial programs. For context, full-year 2025 saw 16 pre-commercial molecule signings; 1Q26 alone has already secured nearly half that count in a single quarter. This run-rate acceleration is a leading indicator: as our capability investments take hold, forward visibility and growth potential are set to compound. Bora’s CDMO business has entered a new phase. Reinforcing this trajectory, the Group’s recently announced acquisition of MacroGenics’ Rockville, Maryland CDMO facility adds a substantial commercial-stage monoclonal antibody programs backlog and manufacturing expertise to the Group. Equipped with five 2,000-liter and two 500-liter single-use bioreactors and integrated QC and analytical labs and currently generating more than half of revenues from commercial manufacturing, the transaction marks a pivotal step in scaling Bora’s integrated biologics CDMO platform, known as Bora Biologics. DS and DP capabilities shall be integrated over the next 12–18 months to offer global biotech customers a single partner from development through commercial supply in the U.S..
On the pharma sales side, the Group faced competition across a handful of core generic products. Upsher-Smith is navigating the competitive landscape with a clear focus on the most margin-accretive opportunities while continuing to scout niche, brand-oriented assets. Near-term, DLS market share has been defended; over the medium term, sustained market share maximization of the infantile spasm franchise coupled with swift pipeline replenishment weighted toward differentiated assets is critical. In the first quarter, we saw unique patients for VIGAFYDE grew by more than 140% over same period last year and a continuous increase in new patients. Both healthy signs of steady execution pace building up to durable resilience in the pharma sales business.”
1Q26 Operational Achievements & 2026 Outlook
Global CDMO Operations
Revenues declined 24.62% year-over-year and 30.15% quarter-over-quarter including internal orders, mainly due to above-mentioned maintenance at fill and finish facility in Maryland, a routine cycle factored into our operating plan, and seasonality at Canada site. To scale biologics CDMO one-stop-shop platform in commercialized projects with SUB (Single Use Bioreactors) in the US; Board of Directors approved the acquisition of Rockville, Maryland based drug substance facility from MacroGenics for US$122.5 million.
Following closing, Bora Group intends to leverage the Rockville Site in cooperation with Tanvex Biopharma (TWSE: 6541), which operates the Group’s biologics CDMO franchise under the “Bora Biologics” brand. Together with Bora’s sterile drug product capabilities, this is expected to expand and strengthen the Group’s end-to-end biologics platform. The Rockville facility has operated as an outsource manufacturing partner since 2022 and is equipped with five 2,000-liter and two 500-liter single-use bioreactors and fully integrated QC and analytical laboratories and has been inspected by both the U.S. FDA and Japan’s PMDA.
During the quarter, 0.44 billion doses, or 108 molecules, were developed and manufactured. Excluding internal orders, the business accounted for 37.73% of consolidated revenues. Contribution from the top 20 global pharmaceutical companies stood at 32.10%.
As the Company continues to expand its CDMO capacity and capabilities, this year’s CAPEX plan is closely linked to the contracting cadence of a key customer anchored at Bora’s North American CDMO network. The Group expects to complete Maple Grove’s capital expenditure program in the first half of the year, sequencing the investment to grow in step with major pharmaceutical partners’ supply chain plans and optimize return on capital deployed.
Pharma Sales Operations
Discontinued operations impact in 2025 has materially abated this quarter, positioning Upsher-Smith to re-accelerate organic growth in 2026. Management has defined two strategic priorities for 2026, designed to enhance capital efficiency and sharpen commercial focus:
First, R&D capital allocation optimization. 505(b)(2) Pipeline programs have been transferred to Salus Therapeutics, an equity-method affiliate. Under this structure, Upsher-Smith retains the right to economic participation in commercial outcomes while shareholders’ exposure to early-stage development and regulatory risks, and associated cash burden is meaningfully reduced. The decision is consistent with the Group’s capital discipline observed across businesses.
Second, institutionalizing pipeline expansion capabilities. An integrated business development and medical affairs function is being established to systematically evaluate in-licensing, co-promotion, and bolt-on opportunities. This integrates Bora’s proven asset-selection and M&A strategy directly into Upsher-Smith’s commercial infrastructure, enabling franchise compounding through targeted external sourcing rather than capital-intensive internal development. These lifecycle initiatives focus but are not limited to pediatric epilepsy opportunities.
Collectively, Management expects Upsher-Smith to evolve fully into a capital efficient, commercially led, and therapeutically centered vehicle designed to deliver sustained shareholder value before exiting 2026.
Recent Investor Conference
Bora will host English online earnings call at 7:30 a.m. Taiwan time on May. 14th, 2026. The event will cover the Company’s 1Q26 financial and business results and 2026 outlook.
English Online Earnings Presentation Link: https://events.q4inc.com/attendee/372103448
Bora will participate in 2026 Yuanta Securities Investment Forum in June. For 1:1 meetings with management, please contact your Yuanta representative.
Bora 2026 Earnings Schedule
Q2 2026: Expected in the 2nd week of Aug 2026
Q3 2026: Expected in the 2nd week of Nov 2026
Q4 2026: Expected in the 2nd week of Mar 2027
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
The announcement forms part of SKYWORTH Solar’s newly unveiled global growth strategy, revealed at the 2026 SNEC Exhibition and Global Customer Summit in Shanghai, where the company introduced its new positioning as a “Global Smart Energy Ecosystem Leader” and outlined plans to accelerate expansion across key international markets.
Thailand has emerged as one of SKYWORTH Solar’s strategic markets in Southeast Asia, driven by rising energy demand, increasing electricity costs for businesses, and growing momentum behind renewable energy adoption.
The opening of the company’s Thailand office at Empire Tower in Bangkok strengthens SKYWORTH Solar’s local presence. It enables the company to provide customers and partners with enhanced support across consultation, project execution, after-sales service, supply chain coordination and project delivery.
“Thailand represents a significant growth opportunity for SKYWORTH Solar as businesses increasingly seek reliable and cost-effective clean energy solutions,” said Wanfei Qu, Chief Investment Officer of SKYWORTH Group, CEO and Director of SKYWORTH Solar. “Our strategy is built on the principle of ‘Global Vision, Local Execution’, combining global expertise with strong local partnerships to support Thailand’s energy transition and long-term sustainability goals.”
As part of its expansion plans, SKYWORTH Solar signed a 100MW C&I solar project MOU with CapSolar, supporting the growing demand for rooftop solar solutions among commercial and industrial businesses.
The company is also strengthening its local ecosystem through investments in project development, financing partnerships and service capabilities. This includes a strategic banking collaboration with ICBC Thai and access to a US$500 million investment fund to support solar project development and deployment in Thailand and other international markets.
One example of SKYWORTH Solar’s growing footprint in Thailand is its 3MW rooftop solar project at UMC Steel Plant in Chonburi Province. The project is expected to generate approximately 4.4 million kWh of clean electricity in its first year, helping reduce energy costs while supporting the facility’s sustainability objectives.
The developments in Thailand were highlighted as part of SKYWORTH Solar’s broader global strategy unveiled at SNEC 2026. The company announced plans to expand its solar, energy storage, and integrated smart energy solutions across Europe, Southeast Asia, the Middle East, and Africa, in response to increasing global demand for renewable energy technologies.
As governments and businesses accelerate their decarbonisation efforts, SKYWORTH Solar aims to support customers through a combination of advanced technology, flexible business models and localised service capabilities.
For more information about SKYWORTH Solar and its clean energy solutions, please visit https://www.skyworth-pv.com.
Hashtag: #SKYWORTH
The issuer is solely responsible for the content of this announcement.
About SKYWORTH
SKYWORTH Solar, the cutting-edge PV brand under SKYWORTH Group, is a global leader in providing comprehensive one-stop solar solutions. Comprehensive end-to-end services are provided, encompassing consulting, design, and product O&M, all supported by a portfolio of self-developed solutions.
As a leading global renewable energy developer, service provider and energy solutions provider, SKYWORTH is actively shaping the future of energy. With a strong presence in EPC services and one-stop product solutions, SKYWORTH delivers high-quality, reliable, and innovative energy solutions. SKYWORTH ‘s commitment to originality and excellence has earned widespread recognition in international markets such as Germany, Italy, the UK, Brazil, and Senegal.
Over five years, nearly 9,000 teachers and students have participated in the Fair to drive youth engagement in innovation and technology
HONG KONG SAR – Media OutReach Newswire – 4 June 2026 – Organised by the Hong Kong Innovation Foundation (‘HKIF’), the Fifth Hong Kong Science Fair (‘Science Fair’) will take place from 27 to 28 June 2026 at the Hong Kong Convention and Exhibition Centre. The event will showcase around 120 shortlisted teams from primary and secondary schools across Hong Kong, presenting creative inventions that integrate artificial intelligence with a diverse range of technology applications. With Sino Group as Principal Patron, the Innovation, Technology and Industry Bureau of the HKSAR Government (ITIB) as the Supporting Bureau, and the Hong Kong Council for Testing and Certification (HKCTC) as Strategic Partner, HKIF is also honoured to have, for the first time, invited the Foundation for the Development of Science and Technology in China as an Advisory Organisation. Representatives from the Foundation will attend the award ceremony to witness the announcement of this year’s winning teams. Consistently a major draw for the community, the Science Fair is now open for online registration with free admission, and the public is warmly invited to attend in person.
Following Hong Kong’s first astronaut, Dr Lai Ka-ying, into space, the local innovation and technology ecosystem has attracted even greater attention. This year’s Science Fair has specially incorporated aerospace engineering elements, enabling the public to learn about the daily work and challenges of payload specialists, gain insight into the reality of aerospace research and development, and spark greater interest among young people in space exploration. Dr Lai launched aboard the Shenzhou-23 manned spacecraft and is expected to remain in space for approximately six months to conduct space science experiments and maintenance tasks. Visitors can express their support and encouragement by creating message cards for her. In addition, UBTECH Robotics, a globally leading enterprise in embodied AI robotics, will participate in the exhibition, showcasing multiple humanoid robots and offering visitors the opportunity to experience the appeal of embodied intelligence up close.
Professor Sun Dong, JP, Secretary for Innovation, Technology and Industry of the HKSAR Government, stated: ‘The Hong Kong SAR Government is fully committed to developing Hong Kong into an international innovation and technology (I&T) centre, with talent being a key driver of this growth. Now in its fifth edition, the Hong Kong Science Fair – organised by the Hong Kong Innovation Foundation – has become an annual flagship I&T education event. It offers students a valuable platform to turn their innovative ideas into practice, deepen their interest and confidence in I&T, and help bring I&T into schools and the wider community, thereby fostering a more innovation-friendly atmosphere. I look forward to seeing more young people unleash their potential through this platform, pursue careers in I&T, and contribute to the high-quality development of Hong Kong and our nation.’
Mr Daryl Ng, SBS, JP, Chairman of the Hong Kong Innovation Foundation and Chairman of Sino Group, said ‘Innovation and technology are key to Hong Kong’s long-term sustainable development and are integral to the country’s 15th Five-Year Plan. It is vital for Hong Kong to strengthen its I&T capabilities and actively contribute to national development, as underscored by the historic moment when Dr Lai Ka-ying became Hong Kong’s first astronaut. We are encouraged to see growing recognition of I&T opening up new opportunities for young people aspiring to pursue scientific research. As the Hong Kong Science Fair enters its fifth edition, its growth has been made possible by the support of the HKSAR Government, industry partners, tertiary institutions, research organisations, and our panels of judges. This year, we are grateful for the guidance and support of the Foundation for the Development of Science and Technology in China. Moving forward, the Science Fair will remain committed to nurturing talent from an early age, bringing together all sectors to promote I&T and inspire more young people to pursue careers in science and technology.’
Professor Anderson Shum, MH, Chairman of Judging Panel, Hong Kong Science Fair, President of The Hong Kong Young Academy of Sciences, said, ‘The Science Fair adopts the format of “integrating competition with exhibition,” enabling students to translate their learning into tangible and verifiable outcomes. This plays an important role in nurturing Hong Kong’s youth I&T ecosystem. I am delighted to have served as a judge for this major event over the years, witnessing students progressively enhance their presentation skills, build confidence, and broaden their horizons through exchanges with experts, participation in workshops and showcasing their work to the public. The standard of participating projects continues to improve each year, with increasing integration of artificial intelligence and diverse technological applications across different fields. Scientific research is a journey that demands passion and perseverance, and the growth of young scientists often begins with curiosity during their primary and secondary school years. Through these exchanges, we hope to leverage the role-model influence of young scientists, inspiring more students to pursue I&T as their lifelong career. I look forward to seeing our younger generation continue to grow and excel in scientific research and innovation, and officially join the community of scientists in the near future to jointly drive Hong Kong’s I&T development.’
Mr Michael Tam, Chief Brand Officer of UBTECH, said, ‘Humanoid robots are among the most promising real-world embodiments of artificial intelligence, reflecting a future in which intelligent systems are deeply integrated with the physical world. As a global pioneer in humanoid robotics, UBTECH has remained at the forefront of innovation for more than 14 years, with a long-standing commitment to I&T education. The company is dedicated to translating advanced technologies into practical, accessible educational resources. Through collaboration with like-minded partners such as the Hong Kong Innovation Foundation, we aim to inspire greater interest and engagement among both teachers and students in humanoid robotics and artificial intelligence. We are committed to supporting the development of Hong Kong’s I&T education ecosystem, helping to nurture future-ready talent and build a strong, sustainable foundation for long-term growth.’
Since its launch in 2021, the Science Fair has attracted participation from over 400 local schools, engaging nearly 9,000 Primary 4 to Secondary 6 students and their teachers. To date, more than 2,200 creative invention submissions have been received and total attendance has exceeded 120,000 visitors. The Science Fair has gradually established itself as a key platform for youth innovation and technology (‘I&T’) exchange and one of Hong Kong’s most representative I&T education initiatives. This year’s response has been enthusiastic, with over 500 project submissions received. Following preliminary judging, around 120 shortlisted teams took part in a series of workshops and mentorship sessions, and will present their projects at the exhibition in late June to compete for top awards. Gold award-winning teams from each category will have the opportunity to participate in the International Exhibition of Inventions Geneva in Switzerland, fostering idea exchange with global I&T talents.
The Hong Kong Science Fair draws tens of thousands of visitors each year. During the exhibition period, the venue will be transformed into a catalyst for city-wide I&T inspiration. In addition to student showcases, five interactive zones will offer hands-on experiences, including DIY bubble bath bomb workshops, freezer-free slushie making, themed games celebrating the Science Fair’s fifth anniversary, and modified remote-controlled cars made from upcycled household appliances, allowing visitors of all ages to explore science and innovation through engaging and enjoyable activities.
- Bulu Bulu Bubble Factory: Blending science with sensory experiences, visitors can mix and mould from scratch to create a delightful ‘bathroom blind box’.
- Shake Shake Ice Factory: Applying the principle of freezing point depression, participants will see how temperature can be rapidly lowered using only salt, ice and water to create personalised slushies — all without a freezer.
- Scan2Play: Scan the QR Code on your phone to join the themed game celebrating the Hong Kong Science Fair’s Fifth Anniversary.
- Racing Homey Kart 2.0: Showcasing the spirit of upcycling and upgrades, visitors can transform old, small household appliances into remote-controlled racing cars and compete on a dedicated track.
- UBTECH Robotics Base: Featuring a wide range of robots, this zone provides a comprehensive showcase of the integration of artificial intelligence with mechanical engineering.
To celebrate the Science Fair’s fifth edition, various special experiences will be introduced. The venue will feature a hidden Science Fair character treasure hunt and check-in activity, through which visitors can redeem curated gifts upon completion. Limited-edition souvenirs, including the ‘HKSF-5 Metal Standee Collection’ and the ‘Special Edition Robo K’ blind boxes, will also be available in limited quantities. All proceeds from the HKSF Bazaar, with no deduction, will go directly to charity to support local community technology initiatives.
The Fifth Hong Kong Science Fair Details:
- Date: 27 to 28 June 2026 (Saturday and Sunday)
- Time: 10:00 am to 6:00 pm
- Venue: Hong Kong Convention and Exhibition Centre, Hall 3FG
- Admission: Free of Charge (Pre-registration online is required)
- Registration Website: https://reghksciencefair.org.hk/public
Photos download: https://shorturl.at/mgawb
Hashtag: #HKIF #ScienceFair
The issuer is solely responsible for the content of this announcement.
Media OutReach
Exploring European Expansion Opportunities for China’s Manufacturing and Logistics Industry
Cushman & Wakefield Hosts “Europe Unlocked” Summits in Shanghai and Guangzhou
HONG KONG SAR – Media OutReach Newswire – 4 June 2026 – This year marks the 50th anniversary of the establishment of diplomatic relations between China and the European Union. The principles of mutual respect, openness, cooperation, and win-win outcomes have long defined China–EU collaboration, laying a solid foundation for Chinese manufacturing enterprises expanding overseas.
Europe has now become a key strategic destination for Chinese companies going global, backed by its high-quality consumer markets, abundant labor force, mature industrial supply chains, and well-established legal framework. In response, Cushman & Wakefield hosted summits on the topic of Europe Unlocked — New Opportunities for China’s Manufacturing & Logistics Industry in Shanghai on June 2 and in Guangzhou on June 4, 2026.
These summits brought together Cushman & Wakefield’s industrial real estate experts from Europe, APAC and Greater China, along with representatives and leading industrial park enterprises from the United Kingdom, Germany, Hungary, Poland, and the Czech Republic. The events provided in-depth insights into the characteristics and advantages of European industrial investment and key industrial park investment opportunities, and attracted broad interest and participation from corporate representatives.
Matthew Bouw, Chief Executive, APAC & EMEA, Cushman & Wakefield, opened the Guangzhou summit and said: “Leveraging our global platform to bring our logistics and industrial sector leads to China to provide in-person intelligence on the current dynamics and strategic opportunities across Europe’s markets is what Cushman & Wakefield is all about. The trading relationship between China and Europe is long established, and is now entering a new phase, as opportunities in e-commerce continue to evolve. Our significant investment in our digital ecosystem, including all things data, analytics, and AI, together with our local brokers’ deep market expertise, is helping clients make well informed, data-driven decisions to drive value for their businesses. It has been our pleasure to partner with our leading European developer clients to host these summits – and we look forward to continuing this working relationship going forward.”
KK Chiu, Chief Executive, Greater China, Cushman & Wakefield, commented: “Over the past five years, European investment in China has continued to grow steadily, with countries such as the United Kingdom, Germany, and Switzerland recording double-digit growth. European companies’ deep familiarity with China’s industrial supply chains also provides strong support for Chinese enterprises to expand into Europe and integrate into local markets. At the same time, Chinese enterprises are increasingly adopting a more strategic and long-term approach to overseas expansion, with greater emphasis on operational resilience, regional diversification, and proximity to customers. Through hosting Europe Unlocked summits, we aim to provide practical market insights and local expertise to help companies better navigate Europe’s diverse industrial landscape and make more informed expansion decisions”
Europe continues to attract strong interest from Chinese enterprises: Chinese inward investment into Europe reached almost €17 billion in 2025, up 67% on 2024 volumes and accounting for nearly a quarter of total global Chinese FDI in 2025[1]. European logistics and industrial markets show positive signs for businesses looking to locate in Europe with occupational demand rallying over the past year, availability of real estate options having grown in many markets since 2022 and developers keen to deliver more high-standard buildings to the market. Additionally, investor conviction in the asset class in Europe remains high with more capital being raised in 2025 to deploy specifically into logistics and industrial real estate assets in Europe than any other single sector[2].
Michael Carson, Head of Supply Chain & Logistics Consulting, APAC & EMEA, Cushman & Wakefield, added: “We’ve built strong credentials in core industrial markets across the region, including Germany, the UK and Eastern Europe. With deep experience, strong connectivity and best in class tools, we will help China manufacturing and logistics enterprises grow business and expand strategically into new markets across the globe.”
Tony Su, Managing Director and Head of Industrial & Logistics Services, China, Cushman & Wakefield, noted: “In recent years, we have drawn on our global resources and professional expertise to successfully support multiple enterprises in entering the European market. We have also assisted dozens of multinational companies in establishing operations in China. Looking ahead, we will continue to leverage our strengths to support the global expansion of Chinese manufacturing and logistics enterprises, providing efficient and professional on-the-ground services.”
————————————————–
1 Rhodium Group
2 Realfin
Hashtag: #Cushman&Wakefield
The issuer is solely responsible for the content of this announcement.
About Cushman & Wakefield
Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 53,000 employees in nearly 350 offices and 60 countries. In Greater China, a network of 23 offices serves local markets across the region. In 2025, the firm reported revenue of $10.3 billion across its core services of Valuation, Consulting, Project & Development Services, Capital Markets, Project & Occupier Services, Industrial & Logistics, Retail, and others. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit www.cushmanwakefield.com.hk or follow us on LinkedIn (
https://www.linkedin.com/company/cushman-&-wakefield-greater-china).
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn